USA. FDA grants marketing authorization of the first device for use in helping to reduce the symptoms of opioid withdrawal
USA. FDA grants marketing authorization of the first device for use in helping to reduce the symptoms of opioid withdrawal
Today, the U.S. Food and Drug Administration granted a new indication to an electric stimulation device for use in helping to reduce the symptoms of opioid withdrawal.
(...)
The NSS-2 Bridge device is a small electrical nerve stimulator placed behind the patient’s ear. It contains a battery-powered chip that emits electrical pulses to stimulate branches of certain cranial nerves. Such stimulations may provide relief from opioid withdrawal symptoms. Patients can use the device for up to five days during the acute physical withdrawal phase. Opioid withdrawal causes acute physical withdrawal symptoms including sweating, gastrointestinal upset, agitation, insomnia and joint pain. (FDA, 15.11.2017)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585271.htm